DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Pavel ME. et al.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Lancet 2011;
378: 2005-2012
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.